Discovery means individualized ovarian, brain cancer therapies

May 16, 2018, Mayo Clinic

Mayo Clinic researchers have discovered that a molecular communication pathway—thought to be defective in cancer—is a key player in determining the effectiveness of measles virus oncolytic cancer treatment in ovarian and aggressive brain cancers. This discovery enabled researchers to develop an algorithm to predict treatment effectiveness in individual patients. The findings appear in the Journal of the National Cancer Institute.

"This discovery and algorithm will allow us to personalize treatment by matching the most appropriate patients with oncolytic virus therapies," says Evanthia Galanis, M.D., senior author of the study. "We'll also know which ones can be helped by combining cancer virotherapy with other immune approaches.

This activation channel, known as the interferon response pathway, had been considered defective in cancer cells. Not so, according to the research team. They performed tests for gene variants and signatures that would identify pathways that resisted the effectiveness of the virus-based treatments that Mayo Clinic has long been developing.

The researchers tested their algorithm on human ovarian and brain tumors transplanted into mice and patients in phase one clinical trials. What they found is a weighted gene signature that could predict treatment sensitivity and resistance. Subsequent research also showed that repurposing ruxolitinib, a drug approved to treat malignant blood disorders, was able to overcome the resistance. This drug, which targets the interferon response pathway, allows the measles virotherapy to increase effectiveness by a factor of 1,000.

The researchers say these findings will help select patients for future involving and shape how those viruses are designed and used in medicine, including the development of effective combination therapies.

Explore further: Combining immunotherapies effective against mouse model of cancer

Related Stories

Combining immunotherapies effective against mouse model of cancer

June 19, 2017
Rhabdomyosarcoma, a cancer made up of cells that normally develop into skeletal muscles, is the most common soft tissue cancer in children. If it is detected early and localized in certain areas, rhabdomyosarcoma is usually ...

Clinical trial uses a genetically engineered virus to fight cancer

August 15, 2017
Sanford Health is the first site in the United States to launch a clinical trial using a genetically-engineered virus that aims to destroy therapy-resistant tumors.

Low dose of targeted drug might improve cancer-killing virus therapy

June 16, 2014
Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive ...

Could viruses take cancer immunotherapy to the next level?

January 3, 2018
Immunotherapy, which helps the body's immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study led by researchers ...

Recommended for you

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Breast cancer drug could create chink in the armour of pancreatic cancer

December 11, 2018
The well-known drug tamoxifen could exploit a weakness in the physical 'scaffolds' around tumours, according to research led by Imperial.

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.